ATOSSA THERAPEUTICS, INC. — Director's Dealing 2021

Jul 7, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ATOSSA THERAPEUTICS, INC. (ATOS)
CIK: 0001488039
Period of Report: 2021-07-02

Reporting Person: WEAVER GREGORY L (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-07-02	Common Stock	M	4581	$5.64	Acquired	4581	Direct
2021-07-02	Common Stock	M	45000	$2.38	Acquired	49581	Direct
2021-07-02	Common Stock	M	45000	$2.52	Acquired	94581	Direct
2021-07-02	Common Stock	M	70000	$1.70	Acquired	164581	Direct
2021-07-02	Common Stock	F	57084	$6.40	Disposed	107497	Direct
2021-07-02	Common Stock	S	107497	$5.58	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-02	Stock Option (right to buy)	$5.64	M	4581	Disposed		Common Stock (4581)	Direct
2021-07-02	Stock Option (right to buy)	$2.38	M	45000	Disposed		Common Stock (45000)	Direct
2021-07-02	Stock Option (right to buy)	$2.52	M	45000	Disposed		Common Stock (45000)	Direct
2021-07-02	Stock Option (right to buy)	$1.70	M	70000	Disposed		Common Stock (70000)	Direct

Footnotes

F1: Reflects the Nasdaq closing price of the Issuer's common stock on July 01, 2021.

F2: Reflects the weighted average sale price. The range of prices for such transaction is $5.51 to $5.65. Open market sale transactions were made on the same day at different prices through a trade order executed by a broker-dealer. The reporting person has reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.

F3: These options were granted on May 24, 2017, vested on a quarterly basis over 12 months and expire 10 years from the grant date.

F4: These options were granted on June 27, 2018, vested on a quarterly basis over 12 months and expire 10 years from the grant date.

F5: These options were granted on May 17, 2019, vested on a quarterly basis over 12 months and expire 10 years from the grant date.

F6: These options were granted on May 15, 2020, vested on a quarterly basis over 12 months and expire 10 years from the grant date.